ArticlemBio2016
Predatory Bacteria Attenuate Klebsiella pneumoniae Burden in Rat Lungs.
Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 114 citations in OpenAlex.
- A Biological Approach to Antimicrobial Resistance in New and Old Bacterial Pathogens.Pathogens (Basel, Switzerland) · 2026Review
- The Biotechnological Applications of Marine Bacteria.Biology · 2026Review
- Predation in microbial communities: gradients of nutritive killing.Nature reviews. Microbiology · 2026Review
- Eying up predatory bacteria: living antimicrobials for ocular infections.Current opinion in ophthalmology · 2026Review
- From microbes to animals: a review on prey choice and prey-predator dynamics across organismal scales.FEMS microbiology reviews · 2026Review
- Review
- Inhaled predatory bacteria-loaded large porous microspheres to eradicate drug-resistantMaterials today. Bio · 2025Article
- A streamlined method to determine the antibiotic resistance of plaque-forming predatory bacteria.Frontiers in microbiology · 2025Article
- Predatory bacteria can intensify lung-injury in a multidrug-resistantFrontiers in microbiology · 2025Article
- Bacteria vs bacteria; the future of antibiotics?New microbes and new infections · 2024Article
- How do Gram-negative bacteria escape predation by Bdellovibrio bacteriovorus?npj antimicrobials and resistance · 2024Review
- Predatory Bacteria in the Treatment of Infectious Diseases and Beyond.Infectious disease reports · 2024Review
- Microbiota and Immunity during Respiratory Infections: Lung and Gut Affair.International journal of molecular sciences · 2024Review
- Predatory bacteria prevent the proliferation of intraocularMicrobiology (Reading, England) · 2024Article
- Postbiotic as Novel Alternative Agent or Adjuvant for the Common Antibiotic Utilized in the Food Industry.Current pharmaceutical biotechnology · 2024Review
- Periodontitis: etiology, conventional treatments, and emerging bacteriophage and predatory bacteria therapies.Frontiers in microbiology · 2024Review
- Chromosome structure and DNA replication dynamics during the life cycle of the predatory bacterium Bdellovibrio bacteriovorus.FEMS microbiology reviews · 2023Review
- Predatory bacteria as potential biofilm control and eradication agents in the food industry.Food science and biotechnology · 2023Review
- Predator-Prey Interactions betweenMicrobiology spectrum · 2023Article
- Two-state swimming: Strategy and survival of a model bacterial predator in response to environmental cues.Biophysical journal · 2023Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- AssociatedDataset
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus are predatory bacteria that naturally-and obligately-prey on other Gram-negative bacteria, and their use has been proposed as a potential new approach to control microbial infection. The ability of predatory bacteria to prey on Gram-negative human pathogens in vitro is well documented; however, the in vivo safety and efficacy of predatory bacteria have yet to be fully assessed. In this study, we examined whether predatory bacteria can reduce bacterial burden in the lungs in an in vivo mammalian system. Initial safety studies were performed by intranasal inoculation of rats with predatory bacteria. No adverse effects or lung pathology were observed in rats exposed to high concentrations of predatory bacteria at up to 10 days postinoculation. Enzyme-linked immunosorbent assay (ELISA) of the immune response revealed a slight increase in inflammatory cytokine levels at 1 h postinoculation that was not sustained by 48 h. Additionally, dissemination experiments showed that predators were efficiently cleared from the host by 10 days postinoculation. To measure the ability of predatory bacteria to reduce microbial burden in vivo, we introduced sublethal concentrations of Klebsiella pneumoniae into the lungs of rats via intranasal inoculation and followed with multiple doses of predatory bacteria over 24 h. Predatory bacteria were able to reduce K. pneumoniae bacterial burden, on average, by more than 3.0 log IMPORTANCE: A widely held notion is that antibiotics are the greatest medical advance of the last 50 years. However, the rise of multidrug-resistant (MDR) bacterial infections has become a global health crisis over the last decade. As we enter the postantibiotic era, it is crucial that we begin to develop new strategies to combat bacterial infection. Here, we report one such new approach: the use of predatory bacteria (Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus) that naturally-and obligately-prey on other Gram-negative bacteria. To our knowledge, this is the first study that demonstrated the ability of predatory bacteria to attenuate the bacterial burden of a key human pathogen in an in vivo mammalian system. As the prevalence of MDR infections continues to rise each year, our results may represent a shift in how we approach treating microbial infections in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.